Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Evotec adds biologics services with Just Biotherapeutics acquisition

by Rick Mullin
May 25, 2019 | A version of this story appeared in Volume 97, Issue 21

 

The contract research firm Evotec has agreed to acquire Seattle-based Just Biotherapeutics, a specialist in machine-learning techniques for biologics design and development, for $90 million. The deal will move Evotec into biologics in therapeutic areas including oncology, central nervous system disorders, metabolics, pain, and infectious diseases. Just Biotherapeutics employs approximately 90 scientists. The firm has an in-house artificial intelligence platform and modular manufacturing technology.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.